Ratings Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Real-time Estimate Cboe BZX Other stock markets 10:14:24 2024-05-20 am EDT			5-day change	1st Jan Change
7.695 ^USD	-2.78%		-24.15%	+10.10%

May. 14	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	CI
May. 02	Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SHATTUCK LABS, INC.	+10.10%	376M	D+
MODERNA, INC.	+35.71%	50.93B	B-
IQVIA HOLDINGS INC.	-0.35%	42.12B	B
LONZA GROUP AG	+49.62%	42.05B	A
CELLTRION, INC.	-4.96%	29.18B	C
ICON PUBLIC LIMITED COMPANY	+12.16%	26.02B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.56%	18.9B	B
BIO-TECHNE CORPORATION	+7.43%	13.21B	B+
UNITED THERAPEUTICS CORPORATION	+24.69%	12.17B	B+
MEDPACE HOLDINGS, INC.	+29.38%	12.16B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes